Public consultation launched on eight anticoagulant rodenticide active substances

Public consultation launched on eight anticoagulant rodenticide active substances


ECHA is collecting information to help the European Commission and Member States decide whether to renew the approval of eight anticoagulant rodenticide active substances.

Helsinki, 15 July 2016 – Active substances with specific hazard classes defined in Article 5 (1) of the Biocidal Products Regulation (BPR) cannot be approved for use in biocidal products unless they meet specific derogation criteria described in Article 5(2).

This public consultation on eight active substances which are used as anticoagulant rodenticides is to gather information to see if any of the derogation criteria are met. The substances are: chlorophacinone, coumatetralyl, warfarin, bromadiolone, difenacoum, brodifacoum, difethialone and flocoumafen.

The Agency wants information on the following criteria related to the risk to humans, animals or the environment, which need to be met if the substances are to be approved:

  • the risk, in a realistic worst case scenario, is negligible, in particular where the product is used in closed systems or under other conditions which aim to exclude contact with humans and release into the environment;
  • the active substance is essential to prevent or control a serious danger to human health, animal health or the environment; or
  • not approving the active substance would have a disproportionately negative impact on society when compared with the risk from the use of the substance.

The consultation is open for 60 days. The final day for comments is 12 September 2016. If any of the information you provide is confidential, you will need to justify it – otherwise it will be published online. The European Commission, together with Member States, will take into account the information collected when deciding whether to approve the renewal of these eight active substances. ECHA is organising this consultation on behalf of the European Commission.